Hugh M. Cole is COO at Jounce Therapeutics, Inc. (JNCE). They have made 9 open-market trades across 2 companies since 2016, most recently 2023-01-10.
CIK 0001604646
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
1 open-market purchase totalling $15K since 2018, against 8 sales. Too few scored purchases to measure a record yet.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| JNCE | SELL | 2023-01-09 | 2023-01-11 | $1.11 | $18K | -4.0% | -11.2% | +49.6% |
| JNCE | SELL | 2022-01-07 | 2022-01-11 | $6.88 | $67K | -2.4% | +21.2% | +0.0% |
| JNCE | SELL | 2021-01-22 | 2021-01-25 | $11.95 | $215K | -1.0% | -16.0% | -25.5% |
| JNCE | SELL | 2021-01-07 | 2021-01-11 | $6.89 | $43K | +74.8% | +72.1% | +27.2% |
| JNCE | SELL | 2020-08-14 | 2020-08-18 | $4.71 | $10K | +4.0% | +100.2% | +55.5% |
| JNCE | SELL | 2020-01-07 | 2020-01-10 | $7.78 | $20K | -12.1% | -20.7% | -36.1% |
| JNCE | SELL | 2019-08-14 | 2019-08-16 | $3.99 | $9K | -9.4% | -14.6% | +30.5% |
| JNCE | BUY | 2018-06-15 | 2018-06-18 | $7.84 | $15K | -5.5% | -1.9% | -15.7% |
| ARIA | SELL | 2016-06-28 | 2016-06-29 | $7.05 | $42K | -1.5% | +27.5% | +87.0% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.